In May 2019, Idience Co., Ltd. (the “Idience”) was established as a 100% subsidiary of Ildong Holdings, a major pharmaceutical company group in Korea. Idience is a clinical stage biopharmaceutical company focused on the development and commercialization of next-generation medicines. We have patient-centered goals to advance and accelerate our lead candidates from preclinical research into clinical trials.

We recently launched a basket trial of clinical phase 1/2 (NCT04174716) for our key pipeline, IDX-1197, a PARP inhibitor for various indications, which will help patients with HRR mutated solid tumors.